Results 1 to 10 of about 4,854,757 (315)

Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry. [PDF]

ESC Heart Fail, 2023
Patients with advanced heart failure (AHF) who are not candidates to advanced therapies have poor prognosis. Some trials have shown that intermittent levosimendan can reduce HF hospitalizations in AHF in the short term.
Dobarro D, Donoso-Trenado V, Solé-González E, Moliner-Abós C, Garcia-Pinilla JM, Lopez-Fernandez S, Ruiz-Bustillo S, Diez-Lopez C, Castrodeza J, Méndez-Fernández AB, Vaqueriza-Cubillo D, Cobo-Marcos M, Tobar J, Sagasti-Aboitiz I, Rodriguez M, Escolar V, Abecia A, Codina P, Gómez-Otero I, Pastor F, Marzoa-Rivas R, González-Babarro E, de Juan-Baguda J, Melendo-Viu M, de Frutos F, Gonzalez-Costello J.   +25 more
europepmc   +2 more sources

Commentary: Cost-Effectiveness of Left Ventricular Assist Devices as Destination Therapy in the United Kingdom [PDF]

Frontiers in Cardiovascular Medicine, 2022
Priyansh Faldu, Kamal Sharma, Shaival Sharma, Smeet Ramani, Nain Dadhania, Ashwati Konat   +5 more
doaj   +4 more sources

Left ventricular assist devices as destination therapy in stage D heart failure. [PDF]

J Geriatr Cardiol, 2019
Mechanical circulatory support (MCS) has increasingly become an important management opportunity for patients with stage D heart failure (HF) with remarkable impact on patient survival and quality of life. Early clinical trials have demonstrated improved
Asleh R, Schettle SS, Khan FW, Kushwaha SS.   +3 more
europepmc   +4 more sources

Implantable ventricular assistance systems (VAD) as a bridge to transplant or as 'destination therapy'. [PDF]

Eur Heart J Suppl, 2021
Heart failure is a complex clinical syndrome associated with a high mortality and morbidity rate. Despite the extensive pharmacological armamentarium, a non-negligible percentage of patients develop advanced heart failure and require further therapies ...
Nesta M, Cammertoni F, Bruno P, Massetti M.   +3 more
europepmc   +2 more sources

Destination Therapy with the magnetically levitated HVAD [PDF]

J Cardiothorac Surg, 2015
Destination therapy (DT) with mechanical circulatory support (MCS) for advanced-stage heart failure patients is an alternative therapy when there is no option of eventually providing the patient with heart transplantation. New generation magnetically levitated pumps encourage a broader use of DT.
Heim C, Rösch J, Zielezinski T, Ballazhi F, Kondruweit M, Weyand M, Tandler R.   +6 more
europepmc   +4 more sources

Consensus Report on Destination Therapy in Japan　- From the DT Committee of the Council for Clinical Use of Ventricular Assist Device Related Academic Societies.

Circulation Journal, 2021
Destination therapy (DT) is the indication to implant a left ventricular assist device (LVAD) in a patient with stage D heart failure who is not a candidate for heart transplantation.
K. Kinugawa, Y. Sakata, M. Ono, S. Nunoda, K. Toda, N. Fukushima, A. Shiose, S. Oishi, Dai Yumino, T. Imamura, M. Endo, Y. Hori, Koichi Kashiwa, Kaoruko Aita, Hiroyuki Kojin, Y. Tejima, Y. Sawa   +16 more
semanticscholar   +3 more sources

Outcomes of Left Ventricular Assist Devices as Destination Therapy: A Systematic Review with Meta-Analysis [PDF]

Life
Background: Heart failure (HF) is a chronic condition that significantly affects morbidity and mortality. For patients with end-stage HF who are not candidates for heart transplantation, left ventricular assist devices (LVADs) provide mechanical ...
Emad Ali Al Khoufi
doaj   +2 more sources

Risk Factors for Development of Stroke in Patients With Continuous-Flow Left Ventricular Assist Device Support as Destination Therapy [PDF]

Texas Heart Institute Journal
Background: Continuous-flow left ventricular assist devices (LVADs) are increasingly used as destination therapy. Although postimplantation stroke rates have been described in the context of bridge-to-transplant or mixed cohorts, stroke development is ...
Ioana B. Florea, MD, MPHS, Nadia H. Bakir, MD, Meghan O. Kelly, MD, Joel D. Schilling, MD, PhD, Gregory A. Ewald, MD, Akinobu Itoh, MD, PhD, Marc R. Moon, MD, Spencer J. Melby, MD, Ralph J. Damiano, Jr, MD, Kunal D. Kotkar, MD, Muhammad F. Masood, MD   +10 more
doaj   +2 more sources

Destination therapy – time for a paradigm change in heart failure therapy

Swiss Medical Weekly, 2013
Heart transplantation is only available for a limited number of patients with end-stage heart failure. Since the arrival of newer ventricular assist devices, mechanical circulatory support constitutes an alternative therapy for patients with ...
Markus Wilhelm, Frank Ruschitzka, Volkmar Falk   +2 more
doaj   +3 more sources

LVAD pannus complicating destination therapy

Human Pathology: Case Reports, 2017
Despite advances in technology, ventricular assist devices still experience a number of complications limiting their long-term use. We present a 73-year-old woman implanted with a left ventricular assist device (LVAD) five years prior due to end-stage ...
Maya Ignaszewski, Margaret Robin B. Cases, Davide Salina, Elizabeth Swiggum, Anson Cheung, Andrew P. Ignaszewski, Michael A. Seidman   +6 more
doaj   +2 more sources